Immunotherapy for allergies and asthma: Present and future

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 276-288

  Mohapatra, Shyam S ^a,b   Qazi, Momina ^a   Hellermann, Gary ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADRENALIN; ALLERGEN; ALLERVAX CAT VACCINE; ALTRAKINCEPT; CGP 51901; COMPLEMENTARY DNA; CORTICOSTEROID; DNA VACCINE; FORMALDEHYDE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12P40; INTERLEUKIN 4 RECEPTOR; LIPOSOME; MONOCLONAL ANTIBODY MAE11; MONOCLONAL ANTIBODY TES-C21; PEPTIDE VACCINE; PHOSPHOLIPASE A2; PLACEBO; RECOMBINANT ALLERGEN; STEROID; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CHEST TIGHTNESS; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HAY FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOTHERAPY; INJECTION SITE REACTION; MOUTH DISEASE; MOUTH PRURITUS; NAUSEA; NONHUMAN; OCULAR PRURITUS; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; SENSITIZATION; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TH1 CELL; THROAT IRRITATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; WHEEZING; ANIMAL; CLINICAL TRIAL (TOPIC); HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TRENDS;

ALLERGENS; ANIMALS; ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 77954658011     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.05.012     Document Type: Review

References (110)

1. Marsh D.G. Genetics of asthma and other atopic diseases. Post-Graduate Education Course 1996, New Orleans, American Academy of Allergy and Immunology, 1-5.
2. Healy J.I., Goodnow C.C. Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol 1998, 16:645-670.
3. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999, 17:255-281.
4. Tsitoura D.C., Verhoef A., Gelder C.M., O'Hehir R.E., Lamb J.R. Altered T cell ligands derived from a major house dust mite allergen enhance IFN-alpha production but not IL-4 production by human CD4 T cells. J Immunol 1996, 157:2160-2165.
5. + T cell responses: the alternative approaches. Annu Rev Immunol 1997, 15:297-322.
6. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994, 12:227-257.
7. Bochner B.S., Undem B.J., Lichtenstein L.M. Immunological aspects of allergic asthma. Annu Rev Immunol 1994, 12:295-335.
8. Pereira C., Botelho F., Tavares B., Lourenço C., Baeta C., Palma-Carlos A.G., Lima J., Chieira C. Kinetics and dynamic evaluation of specific immunotherapy. Eur Ann Allergy Clin Immunol 2004, 36:375-386.
9. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102:558-562.
10. Crameri R. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy. Immunol Allergy Clin North Am 2006, 26:179-189.
11. Cox L., Cohn J.R. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?. Ann Allergy Asthma Immunol 2007, 98:416-426.
12. Calderon M.A, Alves B., Jacobson M., Hurwitz B., Sheikh A., Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 24:CD001936.
13. Nelson H. Does allergen immunotherapy have a role in the treatment of bronchial asthma?. Allergy Asthma Proc 1997, 18:157-162.
14. Des Roches A., Paradis L., Menardo J.-L., Bouges S., Daures J.P., Bousquet J. Immunotherapy with a standardized D. pteronyssinus extract: specific therapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450-453.
15. Senti G., Prinz Vavricka B.M., Erdmann I., Diaz M.I., Markus R., McCormack S.J., Simard J.J., Wüthrich B., Crameri R., Graf N., et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008, 105:17908-17912.
16. Canonica G.W., Bousquet J., Casale T., Lockey R.F., Baena-Cagnani C.E., Pawankar R., Potter P.C., Bousquet P.J., Cox L.S., Durham S.R., et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64(Suppl. 91):1-59.
17. Borish L.C., Nelson H., Lanz M., Claussen L., Whitmore J.B., Agosti J.M., Garrison L. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
18. Bagnasco M., Altrinetti V., Pesce G., Caputo M., Mistrello G., Falagiani P., Canonica G.W., Passalacqua G. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005, 138:197-202.
19. Einarsson R., Renck B., Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy 1988, 43:469-472.
20. Frati F., La Grutta S., Bernardini R., Zampogna S., Scurati S., Puccinelli P., Riario-Sforza G.G., Incorvaia C. Sublingual immunotherapy: administration, dosages, use. Int J Immunopathol Pharmacol 2009, 22:13-16.
21. Lombardi C., Incorvaia C., Braga M., Senna G., Canonica G.W., Passalacqua G. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know?. Allergy 2009, 64:849-854.
22. 2LEN meta-analysis. Allergy 2009, 64:1570-1579.
23. Sieber J., Köberlein J., Mösges R. Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules-IPD meta-analysis. Curr Med Res Opin 2010, 26:925-932.
24. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., Riis B., Grønager P.M., Durham S.R. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121:512-518.
25. Scadding G.W., Shamji M.H., Jacobson M.R., Lee D.I., Wilson D., Lima M.T., Pitkin L., Pilette C., Nouri-Aria K., Durham S.R. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010, 40:598-606.
26. O' Hehir R.E., Gardner L.M., de Leon M.P., Hales B.J., Biondo M., Douglass J.A., Rolland J.M., Sandrini A. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009, 180:936-947.
27. Pfaar O., Klimek L., Sager A., Brautigam M. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy 2010 Feb, [Epub ahead of print].
28. Confino-Cohen R., Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010, 104:73-78.
29. Pfaar O., Klimek L., Fischer I., Sieber J., Amoroso S., Moreno-Aguilar C., Shah K., Mösges R. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol 2009, 150:102-108.
30. Horak F., Zieglmayer P., Zieglmayer R., Lemell P., Devillier P., Montagut A., Mélac M., Galvain S., Jean-Alphonse S., Van Overtvelt L., et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009, 124:471-477.
31. Seidenberg J., Pajno G.B., Bauer C.P., La Grutta S., Sieber J. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol 2009, 19:125-131.
32. Ariano R., Incorvaia C., La Grutta S., Marcucci F., Pajno G., Sensi L., Di Cara G., Sieber J., Yacoub M.R., Frati F. Safety of sublingual immunotherapy started during the pollen season. Curr Med Res Opin 2009, 25:103-107.
33. Dunsky E.H., Goldstein M.F., Dvorin D.J., Belecanech G.A. Anaphylaxis to sublingual immunotherapy. Allergy 2006, 61:1235.
34. de Groot H., Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009, 64:963-964.
35. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008, 63:374.
36. H1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997, 27:1007-1015.
37. Mohapatra S.S. An integrated approach to immune deviation and prevention of allergies and asthma. Allergy Clin Immunol Int 1996, 8:164.
38. Barres M.P., Einarsson R., Bjorksren B. Serum levels of interleukin-4, soluble CD23, and IFN-gamma in relation to the development of allergic disease during the first 18 months of life. Clin Exp Allergy 1995, 25:543-548.
39. Holt P.G. A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet 1994, 344:456-458.
40. Möller C., Dreborg S., Ferdousi H.A., Halken S., Høst A., Jacobsen L., Koivikko A., Koller D.Y., Niggemann B., Norberg L.A., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
41. Arora N., Gangal S.V. Efficacy of liposome-entrapped allergen in down-regulation of IgE response in mice. Clin Exp Allergy 1992, 22:35-42.
42. Wheeler A.W., Henderson D.C., Youlten L.J., Al-Janabi I.I., Hickman B.E., Taylor I.H., Moran D.M. Immunogenicity in guinea pigs and tolerance in grass pollen sensitive volunteers of enteric coated grass pollen allergens. Int Arch Allergy Appl Immunol 1987, 83:354-358.
43. Maasch H.J., Marsh D.J. Standardized extracts modified allergens-allergoids. Clin Rev Allergy 1987, 5:89-106.
44. Wheeler A.W., Whittall N., Cook R.M., Spackman V.M., Moran D.M. T cell reactivity of conjugates of N-formyl-methionyl-leucyl-phenylalanine and rye grass pollen allergens. Int Arch Allergy Appl Immunol 1987, 84:69-73.
45. Vrtala S., Grote M., Ferreira F., Susani M., Stocker B., Kraft D., Valenta R. Humoral immune responses to recombinant tree pollen allergens (Bet v 1 and Bet v 2) in mice: construction of a live oral allergy vaccine. Int Arch Allergy Appl Immunol 1995, 107:290-294.
46. Kumar M., Behera A.K., Matsuse H., Lockey R.F., Mohapatra S.S. A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 1999, 97:515-521.
47. Hsu C.H., Chua K.Y., Tao M.H., Lai Y.L., Wu H.D., Huang S.K., Hsieh K.H. Immunoprophylaxis of allergen induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996, 2:540-544.
48. Raz E., Tighe H., Sato Y., Corr M., Dudler J.A., Roman M., Swain S.L., Spiegelberg H.L., Carson D.A. Inhibition of specific IgE antibody formation by naked plasmid DNA immunization. Proc Natl Acad Sci USA 1996, 93:5141-5145.
49. Rolland J., O'Hehir R. Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr Opin Immunol 1998, 10:640-645.
50. Sloan-Lancaster J., Allen P.M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996, 14:1-27.
51. Rogers B.L., Bond J.F., Craig S.J., Nault A.K., Segal D.B., Morgenstern J.P., Chen M.S., Bizinkauskas C.B., Counsell C.M., Lussier A.M., et al. Potential therapeutic recombinant proteins comprised of peptides containing recombined T cell epitopes. Mol Immunol 1994, 31. 955-366.
52. Sparholt S.H., Larsen J.N., Ipsen H., Schou C., van Neerven R.J. Crossreactivity and T-cell epitope specificity of Bet v 1-specific T cells suggest the involvement of multiple isoallergens in sensitization to birch pollen. Clin Exp Allergy 1997, 27:932-941.
53. Briner T.J., Kuo M.C., Keating K.M., Rogers B.L., Greenstein J.L. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d1. Proc Natl Acad Sci USA 1993, 90:7608-7612.
54. Hoyne G.F., O'Hehir R.E., Wraith D.C., Thomas W.R., Lamb J.R. Inhibition of T cell and antibody responses to house dust mite allergens by inhalation of the dominant T cell epitopes in naive and sensitized mice. J Exp Med 1993, 178:1783-1788.
55. Litwin A., Pesce A.J., Fischer T., Michael M., Michael J.G. Regulation of the human immune responses to ragweed pollen by immunotherapy: a control trial comparing the effect of immunosuppressive peptidic fragments of short ragweed with standard treatment. Clin Exp Allergy 1991, 21:457-465.
56. Michael J.G., Litwin A., Hassert V., Pesce A. Modulation of the immune response to ragweed by peptidic fragments. Clin Exp Allergy 1990, 20:669-674.
57. 2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998, 106:747-754.
58. Maguire P., Nicodemus C., Robinson D., Aaronson D., Umetsu D.T. The safety and efficacy of ALLERVAX-CAT in cat allergic patients. Clin Immunol 1999, 93:222-231.
59. H2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J Allergy Clin Immunol 1999, 104:1015-1023.
60. Kim T.S., De Kryff R.H., Rupper R., Maecker H.T., Levy S., Umetsu D.T. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a helper T cell type 1 dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997, 158:4137-4144.
61. Parronchi P., Mohapatra S., Sampognaro S., Giannarini L., Wahn U., Chong P., Mohapatra S., Maggi E., Renz H., Romagnani S. Effects of interferon-alpha on cytokine profile. T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996, 26:697-703.
62. Mohapatra S.S. IL-12 possibilities. Science 1995, 269:1499.
63. Mujtaba M.G., Villarete L., Johnson H.M. IFN-tau inhibits IgE production in a murine model of allergy and in an IgE-producing human myeloma cell line. J Allergy Clin Immunol 1999, 104:1037-1044.
64. Tulic M.K., Fiset P.O., Manoukian J.J., Frenkiel S., Lavigne F., Eidelman D.H., Hamid Q. Role of toll-like receptor 4 in protection by bacterial lipopolysaccharide in the nasal mucosa of atopic children but not adults. Lancet 2004, 363:1689-1697.
65. Drachenberg K.J., Urban E., Pröll S., Woroniecki S.R. Sublingual specific immunotherapy for adults and children: a post-marketing surveillance study. Allergol Immunopathol (Madr) 2004, 32:76-81.
66. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., Li H., Coffman R., Seyfert V., Eiden J.J., Broide D. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455. Immune Tolerance Network Group.
67. Gauvreau G.M., Boulet L.P., Cockcroft D.W., Baatjes A., Cote J., Deschesnes F., Davis B., Strinich T., Howie K., Duong M., et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958.
68. Zhu D., Kepley C.L., Zhang K., Terada T., Yamada T., Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005, 11:446-449.
69. Kündig T.M., Senti G., Schnetzler G., Wolf C., Prinz Vavricka B.M., Fulurija A., Hennecke F., Sladko K., Jennings G.T., Bachmann M.F. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006, 117:1470-1476.
70. Cookson W. The alliances of genes and environment in asthma and allergy. Nature 1999, 402:B5.
71. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., Jardieu P.M. Humanization of an antibody directed against IgE. J Immunol 1993, 151:2623-2632.
72. Kolbinger F., Saldanha J., Hardman N., Bendig M.M. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng 1993, 6:971-980.
73. Fick R.B. Therapy of allergic pulmonary diseases with anti-IgE antibodies: a review. Pediatr Pulmonol Suppl 1999, 18:115.
74. Corne J., Djukanovic R., Thomas L., Warner J., Botta L., Grandordy B., Gygax D., Heusser C., Patalano F., Richardson W., et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997, 99:879-888.
75. Racine-Poon A., Botta L., Chang T.W., Davis F.M., Gygax D., Liou R.S., Rohane P., Staehelin T., van Steijn A.M., Frank W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 1997, 62:675-690.
76. Casale T.B., Bernstein I.L., Busse W.W., LaForce C.F., Tinkelman D.G., Stoltz R.R., Dockhorn R.J., Reimann J., Su J.Q., Fick R.B., Adelman D.C. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997, 100:110-121.
77. Boulet L.-P., Chapman K.R., Cote J., Kalra S., Bhagat R., Swystun V.A., Laviolette M., Cleland L.D., Deschesnes F., Su J.Q., et al. Inhibitory effect of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997, 155:1835-1840.
78. Fahy J.V., Fleming H.E., Wong H.H., Liu J.T., Su J.Q., Reimann J., Fick R.B., Boushey H.A. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997, 155:1828-1834.
79. Frew A.J. Effects of anti-IgE in asthmatic subjects. Thorax 1998, 53:S52.
80. Boulet L.-P., Turcotte H., Boutet M., Laviolette M. Increased maximal airway response to methacholine during seasonal allergic rhinitis in nonasthmatic subjects: relationships with airway wall thickness and inflammation. Eur Respir J 1995, 8:913-921.
81. Demoly P., Bousquet J. Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997, 155:1825-1927.
82. Fick R.B., Simon S.J., Su J.Q., et al. Anti-IgE (rhumAb) treatment of the symptoms of moderate to severe allergic asthma [abstract]. Ann Allergy Asthma Immunol 1998, 80:80.
83. Metzger W.J., Fick R.B. Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (RhumAb E25) [abstract]. J Allergy Clin Immunol 1998, 101:S231. The E25 Asthma Study Group.
84. Berger W., Gupta N., McAlary M., Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003, 91:182-188.
85. Lin R.Y., Rodriguez-Baez G., Bhargave G.A. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009, 103:442-445.
86. Bang L.M., Plosker G.L. Spotlight on omalizumab in allergic asthma. BioDrugs 2004, 18:415-418.
87. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., Mokhtarani M., Seyfert-Margolis V., Asare A., Bateman K., Deniz Y. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 117:134-140. Immune Tolerance Network Group.
88. Ohara J., Paul W.E. Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 1985, 315:23.
89. Wierenga E.A., Snoek M., De Groot C., Chrétien I., Bos J.D., Jansen H.M., Kapsenberg M.L. Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients. J Immunol 1990, 144:4651-4656.
90. Kotsimbos T.C., Ghaffar O., Minshall E.M., Humbert M., Durham S.R., Pfister R., Menz G., Kay A.B., Hamid Q.A. Expression of the IL-4 receptor subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. J Allergy Clin Immunol 1998, 102:859-866.
91. Mitsuyasu H., Izuhara K., Mao X.Q., Gao P.S., Arinobu Y., Enomoto T., Kawai M., Sasaki S., Dake Y., Hamasaki N., et al. IIe50Val variant of the IL-4R up regulates IgE synthesis and associates with atopic asthma. Nat Genet 1998, 19:119-120.
92. Idzerda R.L., March C.J., Mosley B., Lyman S.D., Vanden Bos T., Gimpel S.D., Din W.S., Grabstein K.H., Widmer M.B., Park L.S., et al. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med 1990, 171:861-873.
93. Lutz R.A., Feng N., Moser R. Binding of interleukin-13 and interleukin-4 to the interleukin (IL)-4/IL-13 receptor of human synovial fibroblasts. J Recept Signal Transduct Res 1999, 19:181.
94. Mosley B., Beckmann M.P., March C.J., Idzerda R.L., Gimpel S.D., VandenBos T., Friend D., Alpert A., Anderson D., Jackson J., et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989, 59:335-348.
95. Jung T., Schrader N., Hellwig M., Enssle K.H., Neumann C. Soluble human interleukin-4 receptor is produced by activated T cells under the control of metalloproteinases. Int Arch Allergy Immunol 1999, 119:23-30.
96. Kruse S., Forster J., Kuehr J., Deichmann K.A. Characterization of the membrane-bound and a soluble form of human IL-4 receptor alpha produced by alternative splicing. Int Immunol 1999, 11:1965-1970.
97. Maliszewski C.R., Sato T.A., Vanden Bos T., Waugh S., Dower S.K., Slack J., Beckmann M.P., Grabstein K.H. Cytokine receptors and B cell functions. I: recombinant soluble receptors specifically inhibit IL-1 and IL-4-induced B cells activities in vitro. J Immunol 1990, 144:3028-3033.
98. Renz H., Enssle K., Lauffer L., Kurrle R., Gelfand E.W. Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. Int Arch Allergy Immunol 1995, 106:46-54.
99. Maliszewski C.R., Morrissey P.J., Fanslow W.C., Sato T.A., Willis C., Davison B. Delayed allograft rejection in mice transgenic for a soluble form of the IL-4 receptor. Cell Immunol 1992, 143:434-448.
100. Meissner N., Kussebi F., Jung T., Ratti H., Baumgarten C., Werfel T., Heusser C., Renz H. A subset of CD8+ T cells from allergic patients produce IL-4 and stimulate IgE production in vitro. Clin Exp Allergy 1997, 27:1402-1411.
101. Sperhake K., Neuber K., Enssle K., Ring J. Effects of recombinant human soluble interleukin-4 receptor on interleukin-4/staphylococcal enterotoxin B-stimulated peripheral mononuclear cells from patients with atopic eczema. Br J Dermatol 1998, 139:784-790.
102. Borish L.C., Nelson H.S., Bensch G., et al. Phase I/II study of soluble interleukin-4 receptor (IL-4R) in adults with moderate asthma. Proceedings of the European Respiratory Society Annual Congress 1999, Abstract P1983.
103. Borish L.C., Nelson H., Nathan B., et al. Phase I nebulization study of recombinant human IL-4 receptor (rhuIL-4R) in adult patients with mild atopic asthma. J Allergy Clin Immunol 1997, 99:S413.
104. Sato J., Asakura K., Murakami M., Uede T., Kataura A. Topical CTLA4-Ig suppresses ongoing mucosal immune response in presensitized murine model of allergic rhinitis. Int Arch Allergy Immunol 1999, 19:197-204.
105. H2 subsets in a murine model of asthma. Am J Respir Cell Mol Biol 1998, 18:453-462.
106. Mathur M., Herrmann K., Qin Y., Gulmen F., Li X., Krimins R., Weinstock J., Elliott D., Bluestone J.A., Padrid P. CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice. Am J Respir Cell Mol Biol 1999, 21:498-509.
107. Payet M., Woodward E.C., Conrad D.H. Humoral response suppression observed with CD23 transgenics. J Immunol 1999, 163:217-223.
108. Christie G., Barton A., Bolognese B., Buckle D.R., Cook R.M., Hansbury M.J., Harper G.P., Marshall L.A., McCord M.E., Moulder K., et al. IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (Fc-epsilonRII). Eur J Immunol 1997, 27:3228-3235.
109. Coyle A.J., Wagner K., Bertrand C., Tsuyuki S., Bews J., Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996, 183:1303-1310.
110. Dasic G., Juillard P., Graber P., Herren S., Angell T., Knowles R., Bonnefoy J.Y., Kosco-Vilbois M.H., Chvatchko Y. Critical role of CD23 in allergen-induced bronchoconstriction in a murine model of allergic asthma. Eur J Immunol 1999, 29:2957-2967.